To date, clopidogrel remains the preferred P2Y12 inhibitor used in combination with an anticoagulant in patients with atrial fibrillation requiring PCI, mainly because of concerns for increased bleeding with prasugrel or ticagrelor in combination with anticoagulation. Here, P2RY12 is linked to atrial fibrillation.